Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 07-Aug-24 4:01 PM View:  | Xu Yuan Director | Fate Therapeutics Inc (FATE) | 06-Aug-24 | Sale (Planned) | 633 | $4.23 | $2,677.59 | (7%) 9.3K to 8.67K | |
| 31-Jul-24 6:05 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 29-Jul-24 | Grant | 200,000 | -- | -- | 127% 158.07K to 358.07K | |
| 31-Jul-24 6:00 PM View: | Tahl Cindy General Counsel and Secretary | Fate Therapeutics Inc (FATE) | 29-Jul-24 | Grant | 200,000 | -- | -- | 140% 142.36K to 342.36K | |
| 05-Mar-24 4:24 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 04-Mar-24 | Sale (Planned) | 2,447 | $7.77 | $19,013.20 | (2%) 103.93K to 101.48K | |
| 30-Jan-24 4:01 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 29-Jan-24 | Sale (Planned) | 1,849 | $5.00 | $9,245.00 | (2%) 105.78K to 103.93K | |
| 10-Jan-24 4:29 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 09-Jan-24 | Sale | 14,391 | $4.37 | $62,888.70 | (4%) 385.64K to 371.25K | |
| 10-Jan-24 4:30 PM View: | Tahl Cindy General Counsel and Secretary | Fate Therapeutics Inc (FATE) | 09-Jan-24 | Sale | 10,874 | $4.37 | $47,519.40 | (7%) 153.24K to 142.36K | |
| 10-Jan-24 4:30 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 09-Jan-24 | Sale | 11,271 | $4.38 | $49,367.00 | (7%) 169.34K to 158.07K | |
| 10-Jan-24 4:29 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 09-Jan-24 | Sale | 7,028 | $4.37 | $30,712.40 | (6%) 112.8K to 105.78K | |
| 03-Jan-24 4:03 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 02-Jan-24 | Sale (Planned) | 5,182 | $3.66 | $18,966.10 | (4%) 117.98K to 112.8K | |
| 28-Dec-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 26-Dec-23 | Purchase | 44,630 | $3.72 | $166,024.00 | < 1% 14.79M to 14.84M | |
| 28-Dec-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 26-Dec-23 | Acquisition (other) | 1,655,370 | $3.72 | $6,157,980.00 | 13% 13.14M to 14.79M | |
| 28-Dec-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 26-Dec-23 | Disposition (other) | 1,655,370 | $3.72 | $6,157,980.00 | (11%) 14.84M to 13.18M | |
| 19-Dec-23 4:01 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 18-Dec-23 | Sale (Planned) | 1,585 | $3.50 | $5,547.50 | (1%) 119.57K to 117.98K | |
| 13-Nov-23 4:01 PM View: | Tahl Cindy General Counsel and Secretary | Fate Therapeutics Inc (FATE) | 09-Nov-23 | Sale (Planned) | 24,363 | $2.40 | $58,471.20 | (14%) 177.6K to 153.24K | |
| 21-Aug-23 4:02 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 18-Aug-23 | Sale | 4,718 | $2.80 | $13,210.40 | (4%) 124.29K to 119.57K | |
| 07-Aug-23 4:01 PM View: | Xu Yuan Director | Fate Therapeutics Inc (FATE) | 04-Aug-23 | Sale (Planned) | 632 | $3.71 | $2,344.72 | (6%) 9.93K to 9.3K | |
| 06-Jul-23 5:19 PM View: | Powl Brian T. Chief Commercial Officer | Fate Therapeutics Inc (FATE) | 05-Jul-23 | Sale | 3,854 | $4.87 | $18,769.00 | (9%) 45.0K to 41.15K | |
| 06-Jul-23 5:18 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 05-Jul-23 | Sale (Planned) | 5,182 | $4.83 | $25,029.10 | (4%) 129.47K to 124.29K | |
| 15-Jun-23 4:05 PM View: | Xu Yuan Director | Fate Therapeutics Inc (FATE) | 14-Jun-23 | Sale (Planned) | 3,460 | $5.58 | $19,306.80 | (26%) 13.39K to 9.93K | |
| 21-Apr-23 9:55 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 21-Apr-23 | Purchase | 256,639 | $6.18 | $1,586,030.00 | 2% 12.88M to 13.14M | |
| 21-Apr-23 9:55 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 20-Apr-23 | Private Purchase | 20,000 | $5.99 | $119,800.00 | < 1% 12.86M to 12.88M | |
| 19-Apr-23 4:07 PM View: | Chu Yu-Waye Chief Medical Officer | Fate Therapeutics Inc (FATE) | 18-Apr-23 | Sale | 2,532 | $6.57 | $16,647.70 | (2%) 143.21K to 140.68K | |
| 17-Apr-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 14-Apr-23 | Sale | 302,339 | $5.84 | $1,765,660.00 | (2%) 13.16M to 12.86M | |
| 17-Apr-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 14-Apr-23 | Acquisition (other) | 5,492,380 | $5.84 | $32,075,500.00 | 42% 13.14M to 18.63M | |
| 17-Apr-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 14-Apr-23 | Disposition (other) | 5,492,380 | $5.84 | $32,075,500.00 | (29%) 18.65M to 13.16M | |
| 17-Apr-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 14-Apr-23 | Purchase | 25,700 | $6.00 | $154,200.00 | < 1% 18.63M to 18.65M | |
| 17-Apr-23 9:30 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 13-Apr-23 | Conversion | 167,205 | -- | -- | 1% 12.97M to 13.14M | |
| 20-Jan-23 4:14 PM View: | Mendlein John Director | Fate Therapeutics Inc (FATE) | 19-Jan-23 | Option Exercise | 28,461 | $1.37 | $38,991.60 | 10% 282.77K to 311.23K | |
| 13-Jan-23 6:20 PM View: | Mendlein John Director | Fate Therapeutics Inc (FATE) | 13-Jan-23 | Purchase | 36,631 | $5.43 | $198,906.00 | 15% 246.14K to 282.77K | |
| 13-Jan-23 4:02 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 12-Jan-23 | Option Exercise | 423 | $1.37 | $579.51 | < 1% 168.92K to 169.34K | |
| 13-Jan-23 6:20 PM View: | Mendlein John Director | Fate Therapeutics Inc (FATE) | 11-Jan-23 | Private Purchase | 88,048 | $5.67 | $499,232.00 | 56% 158.09K to 246.14K | |
| 11-Jan-23 4:06 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 7,331 | $5.24 | $38,414.40 | (5%) 136.8K to 129.47K | |
| 11-Jan-23 4:08 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 10,917 | $5.24 | $57,205.10 | (6%) 179.83K to 168.92K | |
| 11-Jan-23 4:07 PM View: | Plavsic Mark Chief Technical Officer | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 3,418 | $5.24 | $17,910.30 | (3%) 127.12K to 123.7K | |
| 11-Jan-23 4:08 PM View: | Tahl Cindy General Counsel and Secretary | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 11,553 | $5.24 | $60,537.70 | (6%) 189.15K to 177.6K | |
| 11-Jan-23 4:05 PM View: | Chu Yu-Waye Chief Medical Officer | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 7,825 | $5.24 | $41,003.00 | (5%) 151.03K to 143.21K | |
| 11-Jan-23 4:09 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 10-Jan-23 | Sale | 45,907 | $5.24 | $240,553.00 | (11%) 431.55K to 385.64K | |
| 19-Aug-22 6:58 PM View: | Dulac Edward J III Chief Financial Officer | Fate Therapeutics Inc (FATE) | 18-Aug-22 | Sale | 5,135 | $29.81 | $153,051.00 | (4%) 141.94K to 136.8K | |
| 25-Jul-22 6:18 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 22-Jul-22 | Planned Option Sale | 6,246 | $32.08 | $200,356.00 | (1%) 437.79K to 431.55K | |
| 25-Jul-22 6:18 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 22-Jul-22 | Option Exercise | 6,246 | $2.70 | $16,864.20 | 1% 431.55K to 437.79K | |
| 25-Jul-22 6:18 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 21-Jul-22 | Planned Option Sale | 30,000 | $32.88 | $986,361.00 | (6%) 461.55K to 431.55K | |
| 25-Jul-22 6:18 PM View: | Wolchko J Scott President and CEO Director | Fate Therapeutics Inc (FATE) | 21-Jul-22 | Option Exercise | 30,000 | $2.70 | $81,000.00 | 7% 431.55K to 461.55K | |
| 08-Jul-22 4:51 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 07-Jul-22 | Option Exercise | 17,158 | $2.73 | $46,841.30 | 10% 179.83K to 196.99K | |
| 08-Jul-22 4:51 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 07-Jul-22 | Planned Option Sale | 17,158 | $30.23 | $518,686.00 | (9%) 196.99K to 179.83K | |
| 07-Jul-22 4:04 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 06-Jul-22 | Option Exercise | 7,842 | $3.27 | $25,628.70 | 4% 179.83K to 187.68K | |
| 07-Jul-22 4:04 PM View: | Valamehr Bahram Chief R&D Officer | Fate Therapeutics Inc (FATE) | 06-Jul-22 | Planned Option Sale | 7,842 | $30.07 | $235,809.00 | (4%) 187.68K to 179.83K | |
| 06-Jul-22 4:04 PM View: | Plavsic Mark Chief Technical Officer | Fate Therapeutics Inc (FATE) | 05-Jul-22 | Sale | 3,719 | $24.61 | $91,524.60 | (3%) 130.84K to 127.12K | |
| 29-Jun-22 5:02 PM View: | Powl Brian T. Chief Commercial Officer | Fate Therapeutics Inc (FATE) | 27-Jun-22 | Grant | 45,000 | -- | -- | 100% 0 to 45.0K | |
| 13-Jun-22 9:31 PM View: | Redmile Group, LLC Director 10% Owner | Fate Therapeutics Inc (FATE) | 09-Jun-22 | Grant Duplicate | 8,650 | -- | -- | < 1% 12.96M to 12.97M |
